

# SULFORD CV

SULFORD CV is effective against multiple infections. The pharmacological action of Clavulanic acid prevents hydrolysis of Cefpodoxime against beta-lactamase secreting microbes and increases the antibiotic spectrum.

Cefpodoxime, an antibiotic belongs to class of third-generation cephalosporins, is indicated for the treatment of systemic infections including respiratory tract infections, urinary tract infections, otitis media, skin infections and uncomplicated gonorrhoea due to Gram-positive and Gram-negative organisms.

## **Pharmacodynamics**

Cefpodoxime prevents final transpeptidation process of bacterial cell wall peptidoglycan biosynthesis. Cefpodoxime binds with one or more penicillin-binding proteins (PBPs). Clavulanic acid prevents the incidence of drug resistance against Cefpodoxime. The combination is generally well tolerated.

## **Pharmacokinetics**

After oral administration, Cefpodoxime is moderately absorbed (50%) in the GIT. However, food intake delays the GI absorption of the drug and augments plasma concentration. Cefpodoxime and Clavulanic acid are well distributed in respiratory tissues, GIT, urinary tract and breast milk. About 20-30% of Cefpodoxime and Clavulanic acid binds with plasma proteins. The drugs are de-esterified in the intestinal lumen. Cefpodoxime and Clavulanic acid are excreted via the urine as unchanged drug. The plasma half-life of Cefpodoxime and Clavulanic acid is 2-3 hours.

## **Cefpodoxime+Clavulanic acid Indications / Cefpodoxime+Clavulanic acid Uses**

Cefpodoxime and Clavulanic acid can cause pseudomembranous colitis, serious renal toxicity, anaphylactic shock, skin rashes, diarrhoea, abdominal pain, nephritis and nausea or vomiting.

## **Cefpodoxime+Clavulanic acid Adverse Reactions / Cefpodoxime+Clavulanic acid Side Effects**

No information available

## **Precautions**

Cefpodoxime and Clavulanic acid are contraindicated in patients with serious allergy to penicillin, cephalosporin group of antibiotics and renal impairment.

## **Special Precautions**

No information available

## **Other Drug Interactions**

No information available

## **Other Interactions**

No information available

## **Dosage**

For treatment of Respiratory tract infections (Adults):

Consider administration of 100-200 mg of Cefpodoxime and Clavulanic acid, every 12 hours.

For treatment of Respiratory tract infections (Pediatrics):

For children, consider administration of 8-10 mg/kg/day in two divided doses. The maximum dosage should not exceed 400 mg/day.

For treatment of Urinary tract infections (Adults):

Consider administration of 100-200 mg of Cefpodoxime and Clavulanic acid, every 12 hours.

For treatment of Urinary tract infections (Pediatrics):

For children, consider administration of 8-10 mg/kg/day in two divided doses. The maximum dosage should not exceed 400 mg/day.

For Skin infections (Adults):  
Consider administration of 200-400 mg of Sulford cv every 12 hours.

For Skin infections (Pediatrics):  
For children, consider administration of 8-10 mg/kg/day in two divided doses. The maximum dosage should not exceed 400 mg/day.

For Otitis media (Pediatrics):  
For children, consider administration of 8-10 mg/kg/day in two divided doses. The maximum dosage should not exceed 400 mg/day.

For Uncomplicated gonorrhoea (Adults):

### **Food(before/after)**

Sulford CV should be taken preferably with meals

### **List of Contraindications**

#### **SULFORD CV and Pregnancy**

USFDA pregnancy category B. Cefpodoxime and Clavulanic acid may not cause harm to an unborn foetus. Before Cefpodoxime and Clavulanic acid treatment, the patient should discuss with the physician, if they are planning for a pregnancy.

#### **SULFORD CV and Lactation**

Cefpodoxime and Clavulanic acid can pass through the breast milk and harm a feeding infant. Do not breast feed while taking Cefpodoxime and Clavulanic acid.

Store below 25°C. Protect from light.